Granted Patent
B2
US 12,268,667 · App. 17/735,276 · Granted Apr 8, 2025
JAK1 pathway inhibitors for the treatment of prurigo nodularis
Assignee:
Incyte Corporation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.
Claims (20)
1. A method for treating prurigo nodularis in a subject, said method comprising administering to the subject a therapeutically effective amount of JAK1 pathway inhibitor 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
2. The method of claim 1 , wherein the JAK1 pathway inhibitor is a pharmaceutically acceptable salt of 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide.
3. The method of claim 1 , wherein the JAK1 pathway inhibitor is 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide phosphoric acid salt.
4. The method of claim 1 , wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is administered in a daily dose of about 5 mg to about 95 mg on a free base basis.
5. The method of claim 1 , wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is administered in a daily dose of about 45 mg or about 75 mg on a free base basis.
6. The method of claim 1 , wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is administered in combination with a further therapeutic agent.
7. The method of claim 6 , wherein the further therapeutic agent is a neurokinin 1 receptor antagonist.
8. The method of claim 7 , wherein the neurokinin 1 receptor antagonist is aprepitant.
9. The method of claim 6 , wherein the further therapeutic agent is anti-IL-4 and/or anti-IL-13 antibody.
10. The method of claim 9 , wherein the anti-IL-4 and/or anti-IL-13 antibody is dupilumab, lebrikizumab or tralokinumab.
11. The method of claim 6 , wherein the further therapeutic agent is an anti-IL-5 antibody.
12. The method of claim 11 , wherein the anti-IL-5 antibody is benralizumab, mepolizumab, or reslizumab.
13. The method of claim 6 , wherein the further therapeutic agent is an anti-IL-31 antibody.
14. The method of claim 13 , wherein the anti-IL-31 antibody is nemolizumab.
15. The method of claim 1 , wherein the administering comprises administering the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier or excipient.
16. The method of claim 1 , wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is administered in a daily dose of about 10 mg to about 80 mg on a free base basis.
17. The method of claim 1 , wherein the JAK1 pathway inhibitor is 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide.
18. The method of claim 1 , wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is administered in a daily dose of about 45 mg to about 75 mg on a free base basis.
19. The method of claim 1 , wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is administered in a daily dose of about 45 mg on a free base basis.
20. The method of claim 1 , wherein the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is administered in a daily dose of about 75 mg on a free base basis.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 5, 2022
From: SMITH, PAUL; BROWN, KURT ANDREW
To: INCYTE CORPORATION
Reel/Frame 061322/0204 →
Continuity (2)
Provisional Application
63183249
· May 3, 2021
References Cited (400)
US 5521184A
· Zimmerman
· 1996
[cited by applicant]
US 7335667B2
· Rodgers et al.
· 2008
[cited by applicant]
US 7598257B2
· Rodgers et al.
· 2009
[cited by applicant]
US 7834022B2
· Rodgers et al.
· 2010
[cited by applicant]
US 8158616B2
· Rodgers et al.
· 2012
[cited by applicant]
US 8309718B2
· Li et al.
· 2012
[cited by applicant]
US 8410265B2
· Zhou et al.
· 2013
[cited by applicant]
US 8415362B2
· Rodgers et al.
· 2013
[cited by applicant]
US 8486902B2
· Rodgers et al.
· 2013
[cited by applicant]
US 8513270B2
· Arvanitis et al.
· 2013
[cited by applicant]
US 8563541B2
· Arvanitis et al.
· 2013
[cited by applicant]
US 8604043B2
· Li et al.
· 2013
[cited by applicant]
US 8691807B2
· Yao et al.
· 2014
[cited by applicant]
US 8716303B2
· Rodgers et al.
· 2014
[cited by applicant]
US 8722693B2
· Rodgers et al.
· 2014
[cited by applicant]
US 8765734B2
· Huang et al.
· 2014
[cited by applicant]
US 8933085B2
· Rodgers et al.
· 2015
[cited by applicant]
US 8987443B2
· Liu et al.
· 2015
[cited by applicant]
US 9034884B2
· Rodgers et al.
· 2015
[cited by applicant]
US 9181271B2
· Li et al.
· 2015
[cited by applicant]
US 9193733B2
· Rodgers et al.
· 2015
[cited by applicant]
US 9249145B2
· Rodgers et al.
· 2016
[cited by applicant]
US 9358229B2
· Vannucchi et al.
· 2016
[cited by applicant]
US 9359358B2
· Rodgers et al.
· 2016
[cited by applicant]
US 9382231B2
· Li et al.
· 2016
[cited by applicant]
US 9487521B2
· Zhou et al.
· 2016
[cited by applicant]
US 9498467B2
· Leopold et al.
· 2016
[cited by applicant]
US 9549916B2
· Fu et al.
· 2017
[cited by applicant]
US 9655854B2
· Yeleswaram et al.
· 2017
[cited by applicant]
US 9802957B2
· Zhou et al.
· 2017
[cited by applicant]
US 9926301B2
· Li et al.
· 2018
[cited by applicant]
US 9926601B2
· Gertler et al.
· 2018
[cited by applicant]
US 9993480B2
· Vannucchi et al.
· 2018
[cited by applicant]
US 20060106020A1
· Rodgers et al.
· 2006
[cited by applicant]
US 20080312259A1
· Rodgers et al.
· 2008
[cited by applicant]
US 20100113416A1
· Friedman et al.
· 2010
[cited by applicant]
US 20110207754A1
· Li et al.
· 2011
[cited by applicant]
US 20110288107A1
· Parikh et al.
· 2011
[cited by applicant]
US 20120014968A1
· Walsh et al.
· 2012
[cited by applicant]
US 20150065447A1
· Sandor
· 2015
[cited by applicant]
US 20150087662A1
· Li et al.
· 2015
[cited by applicant]
US 20150118229A1
· Voss
· 2015
[cited by examiner]
US 20150246046A1
· Vaddi
· 2015
[cited by applicant]
US 20210346279A1
· Zighelboim et al.
· 2021
[cited by applicant]
CN 101910152
· 2010
[cited by applicant]
CN 102026999
· 2011
[cited by applicant]
JP 2013522214
· 2013
[cited by applicant]
JP 6415543
· 2018
[cited by applicant]
WO WO2000009495
· 2000
[cited by applicant]
WO WO2000053595
· 2000
[cited by applicant]
WO WO2001014402
· 2001
[cited by applicant]
WO WO2001064655
· 2001
[cited by applicant]
WO WO2002000196
· 2002
[cited by applicant]
WO WO2003024967
· 2003
[cited by applicant]
WO WO2003037347
· 2003
[cited by applicant]
WO WO2003099771
· 2003
[cited by applicant]
WO WO2004005281
· 2004
[cited by applicant]
WO WO2004046120
· 2004
[cited by applicant]
WO WO2004056786
· 2004
[cited by applicant]
WO WO2004080980
· 2004
[cited by applicant]
WO WO2005028444
· 2005
[cited by applicant]
WO WO2006056399
· 2006
[cited by applicant]
WO WO2009114512
· 2009
[cited by applicant]
WO WO2011130146
· 2011
[cited by applicant]
WO WO2012068450
· 2012
[cited by applicant]
WO WO2012076063
· 2012
[cited by applicant]
WO WO2012177606
· 2012
[cited by applicant]
WO WO2013036611
· 2013
[cited by applicant]
WO WO2013040863
· 2013
[cited by applicant]
WO WO2014184275
· 2014
[cited by applicant]
WO WO2014184327
· 2014
[cited by applicant]
WO WO2014184328
· 2014
[cited by applicant]
WO WO2014184350
· 2014
[cited by applicant]
WO WO2017096331
· 2017
[cited by applicant]
WO WO2017165571
· 2017
[cited by applicant]
WO WO2018013918
· 2018
[cited by applicant]
WO WO2021076124
· 2020
[cited by applicant]
WO WO2020219640
· 2020
[cited by applicant]
O.E. Molloy, K. N. Bryne, B. Kirby, Successful treatment of recalcitrant nodular prurigo with tofacitinib, Jun. 2, 2020, Clinical and Experimental Dermatology (Year: 2020).
[cited by examiner]
Zeidler. Acta Derm Venereol, 2018; 98: 173-179 (Year: 2018).
[cited by examiner]
Dillon. Nature Immunology, 2004, vol. 5, No. 7 (Year: 2004).
[cited by examiner]
Reddy. Current Rheumatology Reports, 2020, 22:50 (Year: 2020).
[cited by examiner]
Ferreira, American Journal of Clinical Dermatology, 2020, 21:738-798 (Year: 2020).
[cited by examiner]
Aikawa, “Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults,” Nihon Geka Gakkai Zasshi, Sep. 1996, 97(9):771-777 (English abstract only).
[cited by applicant]
Algre et al., “Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor,” Eur. J. Immunol., 1990, 20(3):707-710.
[cited by applicant]
Argentina Office Action in Argentina Application No. 20140101971, dated Nov. 22, 2019, 6 pages.
[cited by applicant]
Australian Office Action in Australian Application No. 2018223058, dated Apr. 8, 2019, 4 pages.
[cited by applicant]
Australian Office Action in Australian Application No. 2018223058, Dec. 17, 2019, 4 pages.
[cited by applicant]
Barabino et al., “Tear film and ocular surface tests in animal models of dry eye: uses and limitations,” Experimental Eye Research, 2004, 79: 613-621.
[cited by applicant]
Beck et al., “Brief Report: Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody,” N. Engl. J. Med., 1994, 330(9): 602-605.
[cited by applicant]
Belzberg, et al., “Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization,” J Invest Dermatol., 2021, 141(9):2208-2218.e14.
[cited by applicant]
Bennett et al., “Proposals for the classification of the myelodysplastic syndromes,” British Journal of Haematology, 1982, 51: 189-199.
[cited by applicant]
Berge et al., “Pharmaceutical salts”, J. Pharma. Science, 1977, 66(1): 1-19.
[cited by applicant]
Bhattacharya et al., “Brittain, ed. Polymorphism in Pharmaceutical Solids,” 2009, p. 327-345.
[cited by applicant]
Blom et al., “Optimizing Preparative LC/MS Configurations and Methods for Parallel Synthesis Purification,” J. Comb. Chem., 2003, 5: 670-683.
[cited by applicant]
Blom et al., “Preparative LC-MS Purification: Improved Compound-Specific Method Optimization,” J. Comb. Chem., 2004, 6: 874-883.
[cited by applicant]
Blom, “Two-Pump at-Column-Dilution Configuration for Preparative Liquid Chormatography—Mass Spectrometry,” J. Comb. Chem., 2002, 4: 295-301.
[cited by applicant]
Bock et al. “Managing drug resistance in cancer: lessons from HIV therapy.” Nature, Jul. 2012, vol. 12, pp. 494-501.
[cited by applicant]
Bolen, “Nonreceptor tyrosine protein kinases”, Oncogene, 1993, 8(8):2025-31.
[cited by applicant]
Bollrath et al., “gp130-Meidated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis,” Cancer Cell, 15: 91-102 (2009).
[cited by applicant]
Borgia et al., “Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus,” Arthritis Rheumatol., 2018, 70(4):616-624.
[cited by applicant]
Borie et al., “Combined Use of the Jak3 Inhibitor CP-690, 550 with Mycophenolate Mofetil to Prevent Kidney Allograft Rejection in Nonhuman Primates,” Transplantation, Dec. 2005, 80(12): 1756-64.
[cited by applicant]
Bosworth, “JAK1/JAK2 Inhibitor Ruxolitinib Is a Rising Start,” Clinical Oncology, Apr. 2011, 06:04, 3 pages.
[cited by applicant]
Boudny, et al., “JAK/STAT signaling pathways and cancer”, Neoplasm, 49:349-355, 2002.
[cited by applicant]
Bowman, et al. “STATs in oncogenesis”, Oncogene, 19:2474-2488, 2000.
[cited by applicant]
Brentjens et al., “Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial,” Mol Ther, 2010, 18:666-668.
[cited by applicant]
Broglie et al., “Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis,” blood advances, Aug. 22, 2017, 1(19):1533-1536.
[cited by applicant]
Bromberg et al., “Inflammation and Cancer: IL-6 and STA T3 Complete the Link,” Cancer Cell, 15 :79-80 (2009).
[cited by applicant]
Brunning and Germing, “Myelodysplastic syndromes/neoplasms” in Chapter 5, Swerdlow, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (ed. 4th edition): Lyon, France: IARC Press, 2008, 4
[cited by applicant]
Bugelski et al., “Monoclonal antibody-induced cytokine-release syndrome,” Expert Review of Clinical Immunology, 2009, 5(5):499-521.
[cited by applicant]
Burdeinick-Kerr et al., “Noncytolytic Clearance of Sindbis Virus Infection from Neurons by Gamma Interferon Is Dependent on Jak/Stat Signaling,” Journal of Virology, Apr. 2009, 83(8):3429-3435.
[cited by applicant]
Burger et al., “Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo”, Mol. Cancer Ther. 2009:8(1), Jan. 2009 pp. 26-35.
[cited by applicant]
Burger, et al., “Gp130 and ras mediated signaling in human plasma cell line IN/a-6: a cytokine-regulated tumor model for plasmacytoma”, Hematol J., 2:42-53, 2001.
[cited by applicant]
Campas-Moya, “Ruxolitinib. Tyrosine-protein kinase JAK1/2 inhibitor, treatment of myelofibrosis, treatment of myeloproliferative neoplasms, treatment of psoriasis”, Drugs of the Future, (Jun. 2010) vol. 35, No. 6, pp. 4…
[cited by applicant]
Candotti et al., “Molecular aspects of primary immuno-deficiencies: lessons from cytokine and other signaling pathways.”, J Clin Invest, 2002, 109(10): 1261-9.
[cited by applicant]
Candotti et al., “Structural and functional basis for JAK3-deficient severe combined immunodeficiency.”, Blood, 1997, 90(10): 3996-4003.
[cited by applicant]
Cetkovic-Cvrlje et al., “Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.”, Clin Immunol, 2003, 106(3): 213-25.
[cited by applicant]
Chalandon, “Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies”, Haematologica, 2005, 90 (7):949-68.
[cited by applicant]
Changelian et al., “Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor”, Science, 2003, 302, 875-878.
[cited by applicant]
Chari et al., “Complete Remission Achieved with Single Agent CNTO 328, an Anti-IL-6 Monoclonal Antibody, in Relapsed and Refractory Myeloma,” Clinical Lymphoma, Myeloma & Leukemia, 2013, 13(3):333-337.
[cited by applicant]
Chen et al., “Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versusl-host disease,” Blood, Jul. 2009, 114(4): 891-900.
[cited by applicant]
Chen et al., “Rhinovirus Induces Airway Epithelial Gene Expression through Double-Stranded RNA and IFN-Dependent Pathways,” Am J of Respir Cell and Mol Bio., Feb. 2006, 34(2):192-203.
[cited by applicant]
Chen et al., “Induction of myelodysplasia by myeloid-derived suppressor cells,” J Clin Invest, Nov. 2013, 123(11): 4595-611.
[cited by applicant]
Chen, et al., “Stat3 Activation in Human Endometrial and Cervical Cancer”, British Journal of Cancer, 96, 591-599, 2007.
[cited by applicant]
Cheson et al., “Report of an international working group to standardize response criteria for myelodysplastic syndromes,” Blood, Dec. 2000, 96(12): 3671-4.
[cited by applicant]
Choy et al., “Therapeutic Benefit of Blocking Interleukin-6 Activity With an Anti-Interleukin-6 Receptor Monoclonal Antibody in Rheumatoid Arthritis,” Arthritis & Rheumatism, 2002, 46(12) 3143-3150.
[cited by applicant]
Cilloni et al., “Emerging drugs for chronic myeloid leukemia”, Expert Opinion on Emerging Drugs, (Jun. 2010) vol. 15, No. 2, pp. 175-184.
[cited by applicant]
Claessens et al., “In vitro proliferation and differentitation of erythyroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis,” Blood, Mar. 2012, 1594-1601.
[cited by applicant]
Clark et al., “Discovery and Development of Janus Kinase (JAK) inhibitors for Inflammatory Diseases,” J Med Chem., 2014, pp. A-P.
[cited by applicant]
Conklyn, M. et al., “The JAK3 inhibitor CP0690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing”, Journal of Leukocyte Biology, 2004, 76, 1248-1255.
[cited by applicant]
Costa Rican Office Action in Costa Rican Application No. 2015-0633, dated Feb. 25, 2020, 13 pages.
[cited by applicant]
Costa Rican Office Action in Costa Rican Application No. 2015-0633, dated Sep. 20, 2019, 14 pages.
[cited by applicant]
Covington et al., “Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1 , for the treatment of inflammatory diseases,” Euro J Pharmacol., Aug. 28, 2020, 885:173505.
[cited by applicant]
Das et al., “Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis,” Blood, Jan. 29, 2016, 127(3):1666-1675.
[cited by applicant]
De Vos et al., (2000). “JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosi…
[cited by applicant]
Deuse, T. et al., “Novel Immunosuppression: R348, a JAK3- and Syk-Inhibitor Attenuates Acute Cardiac Allograft Rejection”, Transplantation, 2008, 85(6) 885-892.
[cited by applicant]
Dudley et al., “A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia,” Biochem J, Sep. 2005, 390(Pt 2): 427-36.
[cited by applicant]
Eghtedar, “Phase II Study of the JAK2 Inhibitor, INCB018424, in Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder Acute Myeloid Leukemia”, American Society of Hematology (ASH) annual meeting …
[cited by applicant]
Eurasian Office Action in Eurasian Application No. 201592199, dated Feb. 4, 2019, 7 pages.
[cited by applicant]
European Search Report in European Application No. 18215671.1, dated May 14, 2019, 5 pages.
[cited by applicant]
Fayad et al., “Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome,” Blood, Jan. 2001, 97(1): 256-263.
[cited by applicant]
Fenaux et al., “A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q,” Blood, Oct. 2011, 118(14): 3765-76.
[cited by applicant]
Fenaux, et al., “Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study,” Lancet Oncol, Mar. 2009, 1…
[cited by applicant]
Ferran et al., “Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation,” Eur. J. Immunol., 1990, 20(3):509-515.
[cited by applicant]
Ferran et al., “Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release,” Clin. Exp. Immunol., 1991, 86(3):537-543.
[cited by applicant]
Flex et al., “Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia,” J Exp Med., 2008, 205(4):751-758.
[cited by applicant]
Fonesca et al., “Interleukin-6 as a key player in systemic inflammation and joint destruction,” Autoimmunity Reviews, 2009, 8(7):538-542.
[cited by applicant]
Fridman et al. “Discovery and Preclinical Development of Selective JAK Inhibitors for the Treatment of Hematological Malignancies” poster presented at European Hematology Association, 12th Congress, Vienna, Austria. Abs…
[cited by applicant]
Fridman et al. “Selective JAK Inhibition is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support” Abstract #0956, presented Sunday, Jun. 15, 2008 at the Eur…
[cited by applicant]
Fridman et al., “Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation”, Journal of Investigative Dermatology, (Sep. 2011) vol. 131, No. 9, pp. 1838-1844.
[cited by applicant]
Fujii et al., “Aberrant expression of serine. thereonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines” International Journal of Cancer 114: 209-218,…
[cited by applicant]
Furtado, “Interleukin 2 signaling is required for CD4(+) regulatory T cell function,” J Exp Med., 2002, 196(6):851-857.
[cited by applicant]
Gaestel et al., “Targeting innate immunity protein kinase signalling in inflammation,” Nat Rev Drug Discov., Jun. 2009, 8(6):480-99.
[cited by applicant]
Gantner at al., “Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor,” Hepatology, 1995, 21(1):190-198.
[cited by applicant]
Gardner et al., “Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management,” ASH 2016, Abstract #586, Dec. 5, 2016, 6 pages.
[cited by applicant]
Goodman, et al., “IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells,” J. Immunol., Sep. 2009, 183: 3170-3176.
[cited by applicant]
Gorre et al., “Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification.” Science, 293:876, 2001.
[cited by applicant]
Gottlieb et al., “Psoriasis: Emerging Therapeutic Strategies”, Nat Rev Drug Disc., 4:19-34 (2005).
[cited by applicant]
Grabbe et al., “Immunoregulatory mechanisms involved in elicitation of allergic—contact hypersensitivity”, Immunol Today, Jan. 1998, 19(1):37-44.
[cited by applicant]
Greenberg, “The myelodysplastic syndromes” in Hoffman, et al., eds. Hematology: Basic Principles and Practice (3rd ed.), Churchill Livingston; 2000:1106-1129.
[cited by applicant]
Greene, Protective Groups in Organic Synthesis, 4th ed., John Wiley & Sons: New Jersey, (2007).
[cited by applicant]
Gregory, et al., “Clinical and laboratory features of myelofibrosis and limitations of current therapies”, Clinical Advances in Hematology and Oncology, (Sep. 2011) vol. 9, No. 9, pp. 1-3.
[cited by applicant]
Grivennikov et al., “IL-6 and STAT3 are required for survival of intestinal epithelial cells and the development of colitis-associated cancer”, Cancer Cell, 15:103-111 (2009).
[cited by applicant]
Groneberg et al., “Animal models of allergic and inflammatory conjunctivitis,” Allergy, Nov. 2003, 58(11): 1101-13.
[cited by applicant]
Grossman, et al., “Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes,” Proc. Natl. Acad., Sci. USA, Aug. 1989, 86: 6367-6371.
[cited by applicant]
Guschin et al., “A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6,” Embo J, 1995, 14(7):1421-1429.
[cited by applicant]
Hardwicke et al., “GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models”, Molecular Cancer Therapeutics, 2009, 8(7):1808-1817.
[cited by applicant]
Hay et al., “Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy,” Immunobio Immunother., Nov. 23, 2017, 130(21):2295-2306.
[cited by applicant]
He et al., “Effectiveness of baricitinib in prurigo-type atopic dermatitis : A case report,” Dermatol Ther., Feb. 26, 2021, 34(2):e14878.
[cited by applicant]
Huang, “Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro”, Cancer Sci. 97(12):1417-23 (2006).
[cited by applicant]
Indian Office Action in Indian Application No. 11174/DELNP/2015, dated Nov. 19, 2019, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2014/038388, dated Nov. 17, 2015, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2019/018066, dated Aug. 18, 2020, 8 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2014/038388, dated Sep. 1, 2014, 9 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2019/018066, dated Apr. 12, 2019, 12 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2021/035400, dated Aug. 12, 2021, 14 pages.
[cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2022/027389, dated Jul. 20, 2022, 21 pages.
[cited by applicant]
Ishizaki, et al., “Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases”, Molecular Pharmacology, 2000, 57, 976-983.
[cited by applicant]
Itagaki, et al., “Expedient Synthesis of Potent Cannabinoid Receptor Agonist (-)-CP55,940”, Organic Letters, 2005; 7(19); 4181-4183.
[cited by applicant]
Jädersten et al., “Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF,” Blood, Aug. 2005, 106(3): 803-11.
[cited by applicant]
James, et al., “A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera”, Nature, 434 (7037):1144-8 (2005).
[cited by applicant]
Janes et al., “Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.”, Nature Medicine, 2010, 16(2):205-213.
[cited by applicant]
Japanese Office Action in Japanese Application No. 2016-514126, dated Feb. 27, 2018, 5 pages (English Translation).
[cited by applicant]
Japanese Office Action in Japanese Application No. 2018-187613, dated Jan. 7, 2020, 4 pages.
[cited by applicant]
Japanese Office Action in Japanese Application No. 2020-543559, dated Feb. 14, 2023, 8 pages.
[cited by applicant]
Jee et al., “Overview: animal models of osteopenia and osteoporosis”, J Musculoskel. Neuron, Interact., 2001, 1(3):193-207.
[cited by applicant]
Juvekar and Ruggeri, “Presentation: Preclinical Efficacy, PD and MoA Studies of Ruxolitinib and Itacitinib in Models of GVHD to Support their Clinical Development,” Nov. 29, 2017, 36 pages.
[cited by applicant]
Kaercher, “Ocular symptoms and signs in patients with ectodermal dysplasia symdromes”, Grafes Arch Clin Exp Ophthalmol, 2004;495-500.
[cited by applicant]
Kamb, “What's wrong with our cancer models?” Nature Reviews Drug Discovery, 2005, 4:161-165.
[cited by applicant]
Kantarjian et al., “Decitabine improves patient outcomes in myelodysplastic syndromes: results of phase III randomized study,” Cancer, Apr. 2006, 106(8): 1794-803.
[cited by applicant]
Kato et al., “Airway Epithelial Cells Produce B Cell-Activating Factor of TNF Family by an IFN-Dependent Mechanism1,” J of Immunol., Nov. 15, 2006, 177(10):7164-7172.
[cited by applicant]
Kaushansky, “Lineage-Specific Hematopoietic Growth Factors”, NEJM, 2006, 354:2034-45.
[cited by applicant]
Kawamura et al. “Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.”, Proc Natl Acad Sci U S A, 1994, 91(14):6374-8.
[cited by applicant]
Kenderian et al., “Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model,” Abstracts, Biol Blood Marrow Transplant, 2017, 23:S18-S391.
[cited by applicant]
Kharas, et al., “ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors.”, Cancer Res., 65(6):2047-2053, Mar. 15, 2005.
[cited by applicant]
Killedar et al., “Early pathogenic events associated with Sjogren's syndrome (SjS)-like disease of the NOD mouse using microarray analysis,” Lab Invest, Dec. 2006, 86(12): 1243-1260.
[cited by applicant]
Kiss, Robert, “Recent developments on JAK2 inhibitors: A patent review”, Expert Opinion on Therapeutic Patents, (Apr. 2010) vol. 20, No. 4, pp. 471-495.
[cited by applicant]
Kola, “Can the pharmaceutical industry reduce attrition rates?” Nature Reviews Drug Discovery, 2004, 3:711-715.
[cited by applicant]
Kortylewski et al., “Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment”, Cancer Cell, 2009, 15:114-123.
[cited by applicant]
Kruh et al., “The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases.”, Proc. Natl. Acad. Sci., Aug. 1990, 87:5802-5806.
[cited by applicant]
Kudlacz et al. “The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia”, European Journal of Pharmacology 582 (2008) 154-161.
[cited by applicant]
Kumar, “Kinase drug discovery approaches in chronic myeloproliferative disorders”, Oncogene, Jun. 18, 2009, 28( 24):2305-23.
[cited by applicant]
Kurzrock et al., “Serum Interleukin 6 Levels Are Elevated in Lymphoma Patients and Correlate with Survival in Advanced Hodgkin's Disease and with B Symptoms,” Cancer Res., May 1993, 52: 2118-2122.
[cited by applicant]
Kurzrock et al., “A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease,” Clin. Cancer Res., published online M…
[cited by applicant]
Lai, et al., “Mechanistic Study on the Inactivation of General Acyl-CoA Dehydrogenase by a Metabolite of Hypoglycin A”, J. Am. Chem. Soc., 1991, 113: 7388-7397.
[cited by applicant]
Larson, “Myelodysplasia: when to treat and how,” Best Pract Res Clin Haematol, 2006, 19(2): 293-300.
[cited by applicant]
Lee et al., “Current concepts in the diagnosis and management of cytokine release syndrome,” Blood, May 29, 2014, 124(2):188-195.
[cited by applicant]
Levine, et al., “Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis”, Cancer Cell, vol. 7, 2005: 387-397.
[cited by applicant]
Léo et al., “Identification of a monoclonal antibody specific for a murine T3 polypeptide,” Proc. Natl. Acad. Sci. USA, 1987, 34:1374-1378.
[cited by applicant]
Levitzki, “Tyrosine kinases as targets for cancer therapy”, Eur. J. Cancer 38(suppl. 5):S11-S18 (2002).
[cited by applicant]
Levy, et al. “INCB018424 A Selective Janus Kinase 1/2 Inhibitor” Presentation at the 50th American Society of Hematology Annual Meeting (ASH), Dec. 8, 2008.
[cited by applicant]
Levy, et al., INCB18424 Discussion presentation at the American Society of Hematology, 49th Annual Meeting and Exposition, Atlanta, GA. Abstract #558, Dec. 10, 2007, 25 pages.
[cited by applicant]
Li et al., “Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates Bad-mediated apoptosis in human pancreatic cell lines” Cancer Research, 20…
[cited by applicant]
Liesveld and Lichtman, Chapter 88. “Myelodysplastic Syndromes (Clonal Cytopenias and Oligoblastic Myelogenous Leukemia)”, in Prchal et al, eds. Williams Hematology. 8th ed., New York: McGraw-Hill; 2010, 30 pages.
[cited by applicant]
Lin et al., “Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction,” Organic Letters, 2009, 11(9):1999-2002.
[cited by applicant]
Lin, “Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines”, Am J Pathol. 167(4):969-80 (2005).
[cited by applicant]
List et al., “Efficacy of lenalidomide in myelodysplastic syndromes,” N Engl J Med, Feb. 2005, 352(6): 549-57.
[cited by applicant]
Lübbert, et al., “Cytogenic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′—deoxycytidine,” Br J Haematol, Aug. 2001, 114(2): 349-57.
[cited by applicant]
Lube et al., “Evans Syndrome at Childhood-Onset Systemic Lupus Erythematosus Diagnosis: A Large Multicenter Study,” Pediatr Blood Cancer, 2016, 63:1238-1243.
[cited by applicant]
Lucet et al., “The structural basis of Janus kinas 2 inhibition by a potent and specific pan-Janus kinase inhibitor,” Blood, 2006, 107(1):176-183.
[cited by applicant]
Macchi, et al., “Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)”, Nature 377:65-8 (1995).
[cited by applicant]
Madden et al. Comparative study of two non-invasive tear film stability techniques. Curr Eye Res, 1994; 13(4):263-9.
[cited by applicant]
Madhusudan et al., “Tyrosine kinase inhibitors in cancer therapy”, Clin Biochem., 2004, 37(7):618-35.
[cited by applicant]
Mainstone et al., “Tear meniscus measurement in the diagnosis of dry eye”, Curr Eye Res, 1996; 15:653-661.
[cited by applicant]
Mancini et al., “RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.”, J. Cellular Biochemistry (2010) LNKD-PUBMED:20014066, XP-002673720 vol. 109, No. 2 (2…
[cited by applicant]
Mascarenhas, “Primary analysis of a phase II open-label trial of CB039110, a selective JAK1 inhibitor, in patients with myelofibrosis,” Haematologica. 2016, pp. 1-22 and Supplemental Data, pp. 1-7.
[cited by applicant]
Maschalidi et al., “Therapeutic effect of JAK 1/2 blockade on the manifestations of hemophagocytic lymphoistiocytosis in mice,” Blood, May 24, 2016, 128(1):60-71.
[cited by applicant]
Maude et al., “Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies,” Cancer J., 2014, 20(2):119-122.
[cited by applicant]
Maxson et al., “Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML,” N. Engl. J. Med., 2013, 368(19):1781-1790.
[cited by applicant]
Mcinnes et al., “Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations,” Arthritis Res Ther., Aug. 2, 2019, 21(1):183.
[cited by applicant]
McMillan, “The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer,” Cancer Treat Rev, Aug. 2013, 39(5): 534-40.
[cited by applicant]
Mesa et al., “Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis”, Expert Opinion on Emerging Drugs England, vol. 14, No. 3 (2009) pp. 471-479.
[cited by applicant]
Mesa, et al., “Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical tr…
[cited by applicant]
Mexican Office Action in Mexican Application No. MX/a/2015/015738, dated Aug. 6, 2019, 5 pages.
[cited by applicant]
Meydan et al., “Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor”, Nature. Feb. 15, 1996;379(6566):645-8.
[cited by applicant]
Milici et al., “Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis”, Arthritis Research & Therapy, 2008, 10:R14 (http://arthritis-research.com/content/10/1/R14) (9 pages).
[cited by applicant]
Minegishi, et al., “Human Tyrosine Kinase 2 Deficiency Reveals Its Requisite Roles in Multiple Cytokine Signals Involved in Innate and Acquired Immunity”, Immunity 25:745-55 (2006).
[cited by applicant]
Mishchenko et al., “Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt”, Eur …
[cited by applicant]
Miyoshi et al., “Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage”, Cornea, 2001;20:743-7.
[cited by applicant]
Molldrem, et al., “Antithymocyte globulin for patients with myelodysplastic syndrome,” Br J Haematol, Dec. 1997, 99(3): 699-705.
[cited by applicant]
Molloy et al., “Successful treatment of recalcitrant nodular prurigo with tofacitinib,” Clin Exper Dermatol., Jul. 18, 2020, 45(7):918-920.
[cited by applicant]
Moreland, et al. “A Randomized Placebo-Controlled Study of INCB018424, a Selective Janus Kinase 1&2 (JAK 1&2) Inhibitor in Rheumatoid Arthritis (RA)” Presentation at the American College of Rheumatology meeting, Oct. 26…
[cited by applicant]
Mullighan, “JAK mutations in high-risk childhood acute lymphoblastic leukemia,” Proc Natl Acad Sci USA, 2009, 106(23):9414-9418.
[cited by applicant]
Mullins, et al., “Prurigo Nodularis,” NLM, StatPearls Publishing, dated Sep. 14, 2021 [retrieved on Aug. 4, 2022], retrieved from URL <https://www.ncbi.nlm.nih.gov/books/NBK459204/>, 6 pages.
[cited by applicant]
Mundle et al., “Evidence for Involvement of Tumor Necrosis Factor-a in Apoptotic Death of Bone Marrow Cells in Myelodysplastic Syndromes,” Am J Hematol, 1999, 60:36-47.
[cited by applicant]
Naka, “The paradigm of IL-6: from basic science to medicine”, Arthritis Res., 2002;4 Suppl 3:S233-42.
[cited by applicant]
Nakagawara, “Trk receptor tyrosine kinases: A bridge between cancer and neural development.” Cancer Letters, 169:107-114, 2001.
[cited by applicant]
Naqvi et al., “A potential role of ruxolitinib in leukemia”, Expert Opinion on Investigational Drugs, Aug. 2011, 20(8):1159-1166.
[cited by applicant]
National Cancer Institute, “FDA Approval for Ruxolitinib Phosphate”, http://www.cancer.gov/cancertopics/druginfo/fda-ruxolitinibphosphate posted Nov. 18, 2011 (3 pages).
[cited by applicant]
Neelapu et al., “Chimeric antigen receptor T-cell therapy—assessment and management of toxicities,” Nat Rev Clin Oncol., 2018, 15(1):47-62.
[cited by applicant]
Neidle, Stephen, “Cancer Drug Design and Discovery,” Elsevier/Academic Press, 2008, pp. 427-431.
[cited by applicant]
Neubauer et al., “Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis”, Cell, 93(3): 397-409 (1998).
[cited by applicant]
Neuner, et al., “Increased IL-6 Production by Monocytes and Keratinocytes in Patients with Psoriasis,” J. Invest. Dermatol, 1991, 97:27-33.
[cited by applicant]
Nicholoff et al., “Recent Insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities”, J. Clin. Invest., 113; 1664-1675 (2004).
[cited by applicant]
Nishimoto et al., “Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody theraphy,”
[cited by applicant]
Norman, “Selective JAK1 inhibitor and selective Tyk2 inhibitor patents,”
[cited by applicant]
Oetjen et al., “Sensory Neurons Co-opt Classical Inunune Signaling Pathways to Mediate Chronic Itch,” Cell, Sep. 1, 2017, 171(1):217-228.e13.
[cited by applicant]
Ortmann, et al., “Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation.” Arthritis Res, 2(1): 16-32 (2000).
[cited by applicant]
Ostojic et al., “Ruxolitinib for the treatment of myelofibrosis”, Drugs of Today, (Nov. 2011) vol. 47, No. 11, pp. 817-827.
[cited by applicant]
Panteli et al., “Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases,” British Journal of Haematology, 2005, 130, 709-715.
[cited by applicant]
Pardanani A., “JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trialsJAK2 inhibitor therapy in MPD”, Leukemia 22, Jan. 23-30, 2008.
[cited by applicant]
Parganas et al., “Jak2 is Essential for Signaling through a Variety of Cytokine Receptors”, (1998). Cell, 93(3): 385-95.
[cited by applicant]
Park et al., “CP-690550, a Janus Kinase Inhibitor, Suppresses CD4 T-Cell-Mediated Acute Graft-Versus-Host Disease by Inhibiting the Interferon-y Pathway,”Transplantation, 2010, 90(8):825-835.
[cited by applicant]
Park et al., “Homogeneous Proximity Tyrosine Kinase Assays: Scintillation Proximity Assay versus Homogeneous Time-Resolved Fluorescence”, Analytical Biochemistry, 1999, 269: 94-104.
[cited by applicant]
Parks, “Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis,” Rheumatologist, Jun. 2013, pp. 1-12 Available from: <http://www.the-rheumatologist.org/details/article/4871781/Tofaci…
[cited by applicant]
Pedranzini et al., “Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells,” Cancer Res., 2006, 66(19):9714-9721.
[cited by applicant]
Peng et al., “Tofacitinib for Prurigo Nodularis: A Case Report,” Clin Cosmet Investig Dermatol., Mar. 1, 2022, 15:503-506.
[cited by applicant]
Pernis et al., “JAK-STAT signaling in asthma.” J Clin Invest, 2002, 109(10): 1279-83.
[cited by applicant]
Peruvian Office Action in Peruvian Application No. 2406-2015, dated Sep. 26, 2019, 17 pages.
[cited by applicant]
Ravin, “Preformulation”, Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, Chapter 76, 1409-1423.
[cited by applicant]
Raza et al., “Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines,” Int J Hematol, Jun. 1996, 63(4): 265-78.
[cited by applicant]
Raza et al., “The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines,” Leuk Res, Nov.-Dec. 1996, 20(11-12): 881-90.
[cited by applicant]
Raza et al., “Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes,” Blood, Jul. 1995, 86(1): 268-76.
[cited by applicant]
Raza et al., “Phase 2 Study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q,” Blood, Jan. 2008, 111(1): 86-93.
[cited by applicant]
Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418.
[cited by applicant]
Reszke et al., “Emerging Therapeutic Options for Chronic Pruritus,” Am J Clin Dermatol., Jun. 30, 2020, 21(5):601-618.
[cited by applicant]
Roberts et al., “Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials,” JAMA, Nov. 2004, 292(17): 2130-40.
[cited by applicant]
Roche, “Bioreversible Carriers in Drug Design,” American Pharmaceutical Association and Pergamon Press, 1987, Front Matter Only, 4 pages.
[cited by applicant]
Rodig et al., “Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.” Cell, 93(3): 373-83 (1998).
[cited by applicant]
Roudebush et al., “Pharmacologic manipulation of a four day murine delayed type hypersensitivity model,” Agents Actions, Jan. 1993, 38(1-2): 116-21.
[cited by applicant]
Rousvoal et al. “Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy”, Transpl Int., 2006 19(12):1014-21.
[cited by applicant]
Samanta et al., “Janus kinase 2: a critical target in chronic myelogenous leukemia”, Cancer Res. Jul. 1, 2006;66(13):6468-72.
[cited by applicant]
Schiffer, “Clinical issues in the management of patients with myelodysplasia,” Hematology Am Soc Hematol Educ Program, 2006: 205-10.
[cited by applicant]
Schiffer, “Myelodysplasia: the good, the fair and the ugly,” Best Pract Res Clin Haematol, Mar. 2007, 20(1): 49-55.
[cited by applicant]
Schindler et al., “Hormones and Signaling: Cytokines and STAT Signaling”, Adv Pharmacol. 2000; 47:113-74.
[cited by applicant]
Schrader et al., “Animal models of dry eye,” Dev Opthalmol, 2008, 41:298-312.
[cited by applicant]
Schram et al., “How I treat hemophagocytic lymphohistiocytosis in the adult patient ,” Blood, 2005, 125(19):2908-2914.
[cited by applicant]
Science IP Search Report, Mar. 2021, 421 pages.
[cited by applicant]
Scott et al., “Jaks, STATs, Cytokines, and Sepsis.” Clin Diagn Lab Immunol, 9(6): 1153-9 (2002).
[cited by applicant]
Search Report ID SR-20210895.01, “Single Crystal Structure Determination of INCB054707 Phosphate,” dated May 20, 2021, 42 pages.
[cited by applicant]
Seki, “STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3”, Int J Oncol. 24(4):931-4 (2004).
[cited by applicant]
Seto et al., “Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice.” J Immunol, 2003, 170(2): 1077-83.
[cited by applicant]
Shah et al., “Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.” Cancer Cell, 2:117-125,…
[cited by applicant]
Shi et al., “The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers”, Journal of Clinical Pharmacology, Dec. 2011, 51(12):1644-1654.
[cited by applicant]
Shimizu et al., “Distinct cytokine profile in juvenile systemic lupus erythematosus-associated macrophage activation syndrome,”Clin Immunol., Feb. 2013, 146(2):73-76.
[cited by applicant]
Silverman et al., “Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B,” J Clin Oncol, Aug. 2006, 24(24): 3895-903.
[cited by applicant]
Silverman et al., “Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B,” J Clin Oncol, May 2002, 20(10): 2429-40.
[cited by applicant]
Simon et al., “Therapeutic strategies for eosinophilic dermatoses,” Curr Opin in Pharmacol., Feb. 10, 2019, 46:29-33.
[cited by applicant]
Sloand et al., “Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy,” J Clin Oncol, May 2008, 26(15): 2505-11.
[cited by applicant]
Smith et al., “Basic pathogenic mechanisms operating in experimental models of acute anteriior uveitis,” Immunol Cell Biol, Dec. 1998, 76(6): 497-512.
[cited by applicant]
Smolen et al., “Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (Option study): a double-blind, placebo-controlled, randomised trial,” Lancet, 2008, 371:987-997.
[cited by applicant]
Snodgrass et al., “Cytokine Release Syndrome: CD19-directed CAR T cell therapy, Bispecifics & Haploidentical HSCT,” Nov. 22, 2017, 33 pages.
[cited by applicant]
Sonbol et al., “Comprehensive review of JAK inhibitors in myeloproliferative neoplasms,” Therapeutic Advances in Hematology, 2013, 4(1): 15-35.
[cited by applicant]
Song et al. “JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer cells and IL-6 Neutralizing Antibodies can Suppress JAK1-STAT3 Signaling,” Mol Cancer Ther., Mar. 2011, 10(3): 481-94.
[cited by applicant]
Spoerl et al., “Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease,” Blood, Jun. 2014, 123(24): 3832-42.
[cited by applicant]
Sriram et al., “Induction of gp130-related Cytokines and Activation of JAK2/STAT3 Pathway in Astrocytes Precedes Up-regulation of Glial Fibrillary Acidic Protein in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Model…
[cited by applicant]
Staerk et. al., “JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor”, J Biol Chem., 2005, 280:41893-41899.
[cited by applicant]
Ständer, et al., “Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis,” N Engl J Med., 2020, 382(8):706-716.
[cited by applicant]
Stirewalt et al., “Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation”, Biol Blood Marrow Transplant. Mar. 2003;9(3):206-12.
[cited by applicant]
Strassmann et al., “Suramin Interferes with Interleukin-6 Receptor Binding in Vitro and Inhibits Colon-26-mediated Experimental Cancer Cachexia in Vivo,” J. Clin. Invest., Nov. 1993, 92: 2152-2159.
[cited by applicant]
Symington et al., “The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation,” Transplantation, Sep. 1992, 54(3): 457-62.
[cited by applicant]
Takemoto et al., “Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.” Proc Natl Acad Sci U S A, 1997, 94(25): 13897-902.
[cited by applicant]
Tamura et al., “Involvement of Human Interleukin 6 in Experimental Cachexia Induced by a Human Uterine Cervical Carcinoma Xenograft,” Clin. Cancer Res., Nov. 1995, 1: 1353-1358.
[cited by applicant]
Taylor et al., “The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients,” 2016 ACR/ARHP Annual Meeting, Abstract No. 2616, Sep. 28, 2016.
[cited by applicant]
Teachey et al., “Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia,” Cancer Discov. 6, 664-679 (2016).
[cited by applicant]
Tefferi, Ayalew, “Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management”, American Journal of Hematology, (Dec. 2011) vol. 86, No. 12, pp. 1017-1026.
[cited by applicant]
Tefferi, et al., “Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis”, Mayo Clinic Proceedings, (Dec. 2011) vol. 86, No. 12, pp. 1188-1191.
[cited by applicant]
Tisoncik et al., “Into the Eye of the Cytokine Storm,” Microbiology and Molecular Biology Reviews, Mar. 2012, 76(1):16-32.
[cited by applicant]
Toyonaga, “Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer”, Cancer Lett. 201(1):107-16 (2003).
[cited by applicant]
Trikha et al., “Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence,” Clinical Cancer Research, 2003, 9: 4653-4665.
[cited by applicant]
Tsoi et al., “Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab,” J Allergy Clin Immunol., 2022, 149:1329-1339.
[cited by applicant]
Vanhoutte, “Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634, ”Arthritis Rheum 64.10 (2012): S1051-1.
[cited by applicant]
Vannucchi et al., “The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms”, Blood: ASH Annual Meeting Absracts, 51st Annual Meeting of the American Society of Hematology…
[cited by applicant]
Vardiman et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,” Blood, Jul. 2009, 114(5): 937-51.
[cited by applicant]
Vardiman et al., “The World Health Organization (WHO) classification of the myeloid neoplasms,” Blood, Oct. 2002, 100(7): 2292-302.
[cited by applicant]
Verma et al., “Jak family of kinases in cancer”, Cancer and Metastasis Reviews, 2003, 22(4):423-434.
[cited by applicant]
Verstovsek, “Therapeutic Potential of JAK2 Inhibitors”, Hematology Am Soc Hematol Educ Program, 2009:636-42.
[cited by applicant]
Verstovsek, et al., Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 558.
[cited by applicant]
Verstovsek, et al., Blood (ASH Annual Meeting Abstracts) 2009 114: Abstract 311.
[cited by applicant]
Verstovsek, et al., Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 313.
[cited by applicant]
Vietnamese Office Action in Vietnamese Application No. 11-2019-01578, dated Apr. 26, 2019, 2 pages.
[cited by applicant]
Winyard and Willoughby, “Methods in Molecular Biology Inflammation Protocols,” Humana Press, 2003, vol. 225, 359 pages.
[cited by applicant]
Wong et al., “IL-17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis,” J Investigative Dermatology, 2020, 140(3):702-706.e2.
[cited by applicant]
www.quora.com, “What is a ‘cytokine storm,’ and what are the diseases that cause that?”, retrieved on Feb. 18, 2018, retrieved from URL <https://www.quora.com/What-is-a-cytokine-storm-and-what-are-the-diseases-that-caus…
[cited by applicant]
Xiaoyang et al., “Knockdown of STAT3 Expression by RNA Interference Inhibits the Induction of Breast Tumors in Immunocompetent Mice”, Cancer Res Apr. 1, 2005 65; 2532.
[cited by applicant]
Xie, et al., “Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1,” J Dermatol., 2019, 46(3):177-185.
[cited by applicant]
Xiong, “Inhibition of JAK1, 2/STAT3 Signaling Induces Apoptosis, Cell Cycle Arrest, and Reduces Tumor Cell Invasion in Colorectal Cancer Cells,” Neoplasia, Mar. 2008, 10(3): 287-297.
[cited by applicant]
Xu et al., “Cytokine release syndrome in cancer Immunotherapy with chimeric antigen receptor engineered T cells,” Cancer Lett., 2014, 343(2):172-178.
[cited by applicant]
Yamamura et al., “Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival,” Br. J. Haematol., 1998, 100: 129-134.
[cited by applicant]
Yamaoka et al., “Janus kinase (JAK) inhibitors in rheumatoid arthritis”, Current Rheumatology Reviews, (Nov. 2011) vol. 7, No. 4, pp. 306-312.
[cited by applicant]
Yao, et al. “Glucocorticoid-Induced Bone Loss in Mice Can Be Reversed by the Actions of Parathyroid Hormone and Risedronate on Different Pathways for Bone Formation and Mineralization”, Arthritis and Rheumatism, 2008, 5…
[cited by applicant]
Yao, et al., “Glucocorticoid Excess in Mice Results in Early Activation of Osteoclastogenesis and Adipogenesis and Prolonged Suppression of Osteogenesis”, Arthritis and Rheumatism, 2008, 58(6):1674-1686.
[cited by applicant]
Yin et al., “Successful treatment of refractory prurigo nodularis with baricitinib,” Dermatol Ther., Jun. 26, 2022, e15642.
[cited by applicant]
Yongjun et al., “Advances in research of tyrosine kinases inhibitor of vascular endothelial growth factor receptor,” Chinese J New Drugs, Dec. 31, 2008, 17(7):544-550.
[cited by applicant]
Coligan et al., “Current Protocols in Immunology,” Wiley Press, Sep. 1992, vol. 3, 21 pages (Chapter Abstracts Only).
[cited by applicant]
Fiskus et al., “Synergistic Activity of Combinations of JAK2 Kinase Inhibitor with PI3K/mTOR, MEK or PIM Kinase Inhibitor Against Human Myeloproliferative Neoplasm Cells Expressing JAK2V617F” J. American Chem. Soc., 52n…
[cited by applicant]
Fridman et al. “Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders” poster presented at the American Society of Hematology, 49th Annual…
[cited by applicant]
Fridman et al. “Discovery and Preclinical Development of Selective JAK Inhibitors for the Treatment of Myeloproliferative Disorders” poster presented at the 4th International Congress on Myeloproliferative Diseases and …
[cited by applicant]
Fridman et al. “Efficacy and Tolerability of Novel JAK Inhibitors in Animal Models of Rheumatoid Arthritis” poster presented at the ACR/ARHP (American College of Rheumatology/Association of Rheumatology Health Professio…
[cited by applicant]
Harigai et al., “Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of all Headache?,” Drugs, Jul. 2020, 80(12): 1183-1201.
[cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2022/027389, mailed on Oct. 24, 2023, 12 pages.
[cited by applicant]
Lemp, “The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Eye Workshop,” The Ocular Surface, Apr. 2007, 5(2): 75-92.
[cited by applicant]
Lübbert, et al., Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized …
[cited by applicant]
Mesa, et al. “INCB018424, A Selective JAK 1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF)” Poster #1760 at the American Society of Hematolo…
[cited by applicant]
Punwani et al., “Efficacy and safety of topical INCB018424, a selective Janus kinase 1 & 2 (JAK1&2) inhibitor in psoriasis,” Journal of the American Academy of Dermatology, Mar. 2009, vol. 60. No. 3.
[cited by applicant]
Punwani et al., Poster/presentation, “Initial Efficacy and Safety of Topical INCYB018424 Cream, a Selective Janus Kinase 1&2 (JAK 1&2) Inhibitor in Psoriasis” 17th Congress of the European Academy of Dermatology and Ven…
[cited by applicant]
Tefferi et al. “The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State that is Favorably Altered by INCB018424, A Selective Inhibitor of JAK1/2” Poster #2804 at the American Society of Hematolo…
[cited by applicant]